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Fragile X syndrome (FXS) is the most common form
of inherited intellectual disability, resulting from
a CGG repeat expansion in the fragile X mental retar-
dation 1 (FMR1) gene. Here, we report a strategy
for CGG repeat correction using CRISPR/Cas9
for targeted deletion in both embryonic stem cells
and induced pluripotent stem cells derived from
FXS patients. Following gene correction in FXS
induced pluripotent stem cells, FMR1 expression
was restored and sustained in neural precursor cells
and mature neurons. Strikingly, after removal of the
CGG repeats, the upstream CpG island of the
FMR1 promoter showed extensive demethylation,
an open chromatin state, and transcription initiation.
These results suggest a silencing maintenance
mechanism for the FMR1 promoter that is dependent
on the existence of the CGG repeat expansion.
Our strategy for deletion of trinucleotide repeats pro-
vides further insights into the molecular mechanisms
of FXS and future therapies of trinucleotide repeat
disorders.
INTRODUCTION
Fragile X syndrome (FXS) is the most common inherited form
of intellectual disability with an incidence in males of one in
3,600, and it is caused by the silencing of the fragile X mental
retardation 1 (FMR1) gene located on chromosome X (Crawford
et al., 2001; O’Donnell and Warren, 2002; Penagarikano et al.,
2007). The causative mutation in FXS is a triple nucleotide
CGG repeat expansion located in the 50-UTR of FMR1 (Fu
et al., 1991; Verkerk et al., 1991). Although healthy individuals
harbor between 5 and 55 copies of the CGG repeats, affected
patients harbor more than 200 copies and are considered
as having a full mutation (Pearson et al., 2005). It has been
demonstrated that the silencing of FMR1 in patients with a234 Cell Reports 13, 234–241, October 13, 2015 ª2015 The Authorsfull mutation is correlated with abnormal DNA methylation
and epigenetic changes in the CGG repeats (Coffee et al.,
2002; Urbach et al., 2010; Eiges et al., 2007; Avitzour et al.,
2014; Tabolacci et al., 2008).
We previously have generated models for FXS in embryonic
stem cells (ESCs) (Eiges et al., 2007) and in induced pluripotent
stem cells (iPSCs) (Urbach et al., 2010), and, using these
models, we have demonstrated both the temporal silencing
of FMR1 during embryonic development and the ability to
generate FXS neurons. We also have shown that the demethy-
lating agent 5-azacytidine (5-AzaC) can induce reactivation of
FMR1 expression in FXS-iPSCs and partial demethylation of
the FMR1 promoter, suggesting a direct effect of methylation
on the silencing of FMR1 (Bar-Nur et al., 2012). However,
the interrelationship between the CGG repeats found at the
50-UTR of FMR1 and the silencing of the gene is still obscure.
It is also unclear whether a silenced methylated gene promoter
could be demethylated upon removal of the downstream CGG
repeats, and whether these changes would in turn affect gene
expression.
The prokaryotic Type II clustered regularly interspaced short
palindromic repeat (CRISPR)/CRISPR-associated 9 (Cas9) sys-
tem, also known as RNA-guided endonucleases (RGENs), acts
as an adaptive immune response in bacteria and archaea
(Horvath and Barrangou, 2010; Wiedenheft et al., 2012). During
the last few years, this system has been remodeled and adapted
for genome editing (Cong et al., 2013; Mali et al., 2013; Cho
et al., 2013; Wang et al., 2013). The Cas9 nuclease (derived
from Streptococcus pyogenes) can be guided by a single-guide
RNA (sgRNA) that is complementary to the target DNA via
Watson-Crick base pairing and via the 50-NGG motif known as
the protospacer adjacent motif (PAM) (Jinek et al., 2012). The
guided delivery of the Cas9 nuclease to its target site results
in a DNA double-strand break (DSB) 3 bp upstream of the
PAM sequence. The introduction of a DSB at a genomic
locus increases the occurrence of insertion/deletion mutations
or homology-directed recombination (HDR) by cellular repair
mechanisms.
Patient-specific iPSCs derived from affected individuals are
suggested as a promising therapeutic source to treat and study
genetic disorders by correcting the causal mutations. In this
work, we utilized the RGEN system to edit the CGG repeats
located at the 50-UTR of FMR1. We show that removal of
the CGG repeats can induce reactivation of silenced FMR1
gene expression in FXS iPSC systems and their derivatives.
Furthermore, we demonstrate complete DNA demethylation of
the FMR1 promoter in FXS-edited lines, suggesting that the
DNA methylation status of the FMR1 promoter in FXS iPSCs is
dependent upon the CGG repeats and is constantly maintained
according to the methylation status of the repeats. This study
demonstrates that a full mutation of a CGG repeat expansion
can be corrected using engineered nucleases in a patient-spe-
cific iPSC systemwithout the use of template DNA for correction.
This strategy may provide a promising applicable approach in
the study of gene and cell therapy for future treatment of FXS
and other genetic diseases caused by abnormal trinucleotide
repeat expansions.
RESULTS
Sequence Analysis of the 50-UTR within the FMR1 Gene
To identify DNA sequences in the FMR1 gene that would enable
deletion of the CGG repeats, we determined the sequence of
the CGG repeats and their flanking regions (herein termed
upstream and downstream of the CGG repeats) in wild-type
(WT) and FXS iPSCs and ESCs. We first amplified the 50-UTR
from WT cell lines using the primer sets FMR1-F and FMR1-R
(Figure S1A). In the case of FXS iPSCs and ESCs, we amplified
the upstream and downstream regions of the CGG repeats sepa-
rately, using FMR1-F/FMR1-R1 or FMR1-F1/FMR1-R primers,
respectively (Figure S1A). This is because conventional PCR
methods have difficulty amplifying fully mutated CGG repeats
that are more than 200 copies long, which is the case in FXS
patients. Indeed, previous reports have indicated that the FXS
iPSCs used in this study harbored more than 450 repeats,
and the FXS ESCs in this study harbored more than 200 CGG
repeats (Gray et al., 2007; Eiges et al., 2007). Our WT cells
showed repeated structures of nine to ten CGG trinucleotides
linked with or without a single AGG trinucleotide (Figure S1B;
Table S1). Interestingly, we found that the sequences of the flank-
ing upstream and downstream regions inWT and patient-derived
cells were identical (Figure S1B). The FMR1 gene resided on the
X chromosome and appeared in only one allele in male cells;
we thus hypothesized that DSB-induced deletions of the CGG
repeats would be resolved by non-homologous end joining
(NHEJ) between the sequences flanking the triplet repeats.
RGEN-Induced Mutations within the FMR1 Gene in
HEK293T Cells
Next, we generated RGEN composed of the Cas9 nuclease and
sgRNA that targeted the end of the upstream sequence of the
CGG repeats (Figure 1A). To confirm the RGEN genome-editing
activities, a T7 endonuclease I (T7E1) assay was performed in
HEK293T cells. The RGEN activity was relatively high, inducing
mutations with a frequency of 41% at the target site (Figure 1B).
In additional sequencing analyses, large deleted sequences as
well as small insertions and deletions (indels) were found at the
RGEN target site (Figure S1C). Because off-target mutationsCmay cause undesirable effects when using RGEN systems (Fu
et al., 2013; Hsu et al., 2013; Pattanayak et al., 2013; Cho
et al., 2014), we investigated whether these mutation types
were induced by the RGEN system used in this study. The four
potential off-target sites most similar to the on-target site in the
human genomewere searched using the Cas-OFFinder program
(Figure S1D). We then verified that the RGEN system used in this
study did not create any detectable off-target mutations at these
sites using the T7E1 assay (Figure S1E).
Targeted Genomic Editing of CGG Repeats in Patients’
iPSCs and ESCs
To correct FXS in the patients’ cells, we utilized our engineered
RGENs to edit FXS iPSCs and FXS ESCs. Following electropora-
tion of Cas9 and sgRNA plasmids into WT cells, FXS iPSCs, and
FXS ESCs, PCR-based genotyping analysis was performed to
screen for edited clones. Of all the edited WT iPSC and WT
ESC clones analyzed, only clones with a CGG repeat deletion of
approximately 90 bp from their parental lines were selected for
further analysis as controls (Table S1). In FXS iPSCs and FXS
ESCs, we only selected clones that had PCR products of similar
size to those of the 90 bp-deletedWT cells (Figure 1C). Following
the screen and further passaging, two to three edited clones from
each cell type with CGG repeat deletions were established out of
approximately 100 colonies (2%–3% efficiency) and confirmed
using PCR-based genotyping (Figure 1C). All edited clones dis-
played a deletion of the CGG repeat sequence at the 50-UTR
of FMR1 (Figure 1D). This result demonstrates that targeted
DSBs upstream of the CGG repeat are induced by the Cas9
nuclease and can cause large deletions of abnormally mutated
repeats. Finally, to verify a complete ablation of the CGG repeats
in the selected edited FXS iPSCs, we analyzed our FXS iPSCs
as well as the edited FXS iPSC clones E1 and E3 using the
AmplideX FMR1 PCR kit. Analysis revealed that, while the parent
FXS iPSCs harbored more than 200 repeats, the edited FXS
iPSC clones showed no detection of CGGs (Figure S1F).
Reactivation of FMR1 Gene Expression in Edited FXS
iPSC and FXS NPC Clones
Based on the encouraging results of the genomic DNA editing,
we analyzed whether deletion of the CGG repeats would lead
to the reactivation of FMR1. To assess the reactivation of the
silenced FMR1 gene, mRNA levels were evaluated in WT and
FXS iPSCs, in both edited and non-edited isogenic cell lines,
using qPCR analysis. Unlike in FXS patient iPSC models, the
expression of FMR1 remains active in FXS ESCs, and silencing
is sometimes obtained only after a very long differentiation into
mature neurons (Urbach et al., 2010). Because of this difference
between patient-derived iPSCs and ESCs, we chose to focus on
reactivation of the FMR1 gene by genome editing in the iPSC
model system. Interestingly, we found that, in edited FXS iPSCs
(FXS iPSC clones E1 and E3), the reactivation of the silenced
FMR1 mRNA occurred after deletion of the CGG repeats. We
also found that FMR1 mRNA levels were restored to levels
similar to those seen in control WT cells. Furthermore, the dele-
tion itself did not show any major change to the transcription
of FMR1 in edited WT iPSCs compared with their parental non-
edited cells (Figure 1E).ell Reports 13, 234–241, October 13, 2015 ª2015 The Authors 235
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Figure 1. RGEN-Induced Mutations and
Reactivation of FMR1
(A) The RGEN-binding site is shown in a schematic
view of the FMR1 50-UTR; the PAM sequence is
shown in red.
(B) Mutations at the RGEN target site were esti-
mated in HEK293T cells by the T7E1 assay. The
asterisk indicates the predicted position of DNA
bands cleaved by T7E1.
(C) PCR analysis of genomic DNA from wild-type
(WT), patient (FXS), and edited (E) lines is shown.
(D) PCR products amplified from each cell type
were analyzed for their sequences. Each RGEN
target sequence is underlined, respectively. The
PAM sequence is indicated in red, the cleavage
site is represented as the red triangle, the deleted
bases are represented as dashes, and the inserted
bases are represented as lowercase letters. The
expression of FMR1 mRNA in WT cells (WT), FXS
patient cells (FXS), and edited clones (E1 to E3)
was analyzed.
(E and F) The qPCRwas used to detect expression
of the FMR1 gene in undifferentiated cells (E) and
expendable NPCs (F). GAPDH expression was
used for normalization. Error bars represent SE
(n = 3 independent experiments).To ensure that the reactivation seen in iPSCs is retained
through neural differentiation, we induced neural rosettes from
WT, FXS-edited, and non-edited isogenic cell lines. No differ-
ence in the formation rate of neural rosettes was observed
between edited iPSC and ESC lines when compared with their
parental lines, indicating that all lines used in the study have
a similar potential to differentiate into early neural cells (Fig-
ure S2A). Transcription of FMR1 was maintained in neuronal
precursor cells (NPCs) differentiated from all edited FXS iPSC
lines (namely, FXS iPSC E1, E2, and E3), with similar expression
levels to those seen in WT iPSCs (Figure 1F).
Analysis of the Methylation Status within the Promoter
Region of FMR1
After successfully reactivating FMR1 at the RNA level, we sought
to understand whether the changes seen in expression corre-
lated with epigenetic changes in the promoter region of FMR1.236 Cell Reports 13, 234–241, October 13, 2015 ª2015 The AuthorsWe first analyzed the methylation status
of the FMR1 promoter in iPSCs in order
to determine whether the deletion of
the CGG repeats affected the upstream
CpG island of the promoter. Using pyro-
sequencing, we analyzed 22 CpG sites
between 395 to 256 bp from the
FMR1 transcription start site (Figure 2A).
The results indicated that, prior to the
removal of the CGG repeats in FXS iPSCs
by RGEN, all CpG sites were hypermethy-
lated, with most sites reaching 100%
methylation (Figure 2B). When analyzing
the same 22 CpG sites at the FMR1 pro-
moter in our edited FXS iPSC clones, wedetected a dramatic demethylation of the promoter, with many
CpG sites reaching methylation levels similar to those observed
in WT cells (Figure 2B). Quantification of the pyrosequencing
results showed that the average methylation level of the WT
iPSC promoter was 0.4%, and in FXS iPSCs the average pro-
moter methylation reached 87.4%. When analyzing the edited
FXS iPSCs, we detected a striking decrease in average methyl-
ation of the promoter, which was only 10% in FXS iPSC clone E1
and a mere 0.8% in FXS iPSC clone E3, similar to WT iPSCs
(Figure 2C).
Methylation levels of the FMR1 promoter also were analyzed
in NPCs derived from the aforementioned WT, FXS, edited WT,
and edited FXS iPSCs. Similar to what was observed in the
iPSCs, NPCs also showed a significant change in promoter
methylation levels between edited and non-edited FXS clones.
Although both WT NPCs and edited WT NPCs showed hypome-
thylation, with almost all sites being completely non-methylated,
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Figure 2. Methylation and Chromatin Con-
formation Analysis of the FMR1 Promoter
(A) The 22 CpG sites used for the methylation
analysis are clustered at the promoter of FMR1,
395 to 256 bp from the gene’s transcription
start site.
(B) Pyrosequencing was performed on 22 CpGs of
the FMR1 promoter for WT, FXS, and edited FXS
iPSCs (top), as well as on both edited and non-
edited WT and FXS NPCs (bottom). FXS iPSCs
show full methylation prior to gene editing and
extensive de-methylation after editing for most
sites (top). In NPCs, both WT and edited WT NPCs
show hypomethylation, and FXS NPCs show hy-
permethylation of the promoter in all analyzed
sites. In contrast to FXS NPCs, both edited FXS
NPC clones show strong hypomethylation, with
most sites showing methylation levels similar to
WT levels (bottom).
(C) Quantification of methylation levels at all
CpG sites shows the average percentage of
methylation for each cell type. WT iPSCs show
hypomethylation and FXS iPSCs show hyper-
methylation. After editing the CGG repeats, FXS
iPSCs show hypomethylation, similar to WT iPSCs
(left graph). Similar percentages of methylation
were observed in NPCs derived from the afore-
mentioned cells (right graph).
(D) Chromatin immunoprecipitation was per-
formed on FXS iPSCs and edited FXS iPSCs.
Graphs show relative fold enrichment for different
chromatin markers. APRT marks open chromatin,
CRYAA marks closed chromatin, and FMR1 was
compared with both. Results show that the
FMR1 promoter in FXS iPSCs resembles markers
of closed chromatin, and, after editing, the pro-
moter is enriched for markers of open chromatin.
Error bars represent SE; *p < 0.05, **p < 0.005,
using Student’s t test.FXS NPCs displayed hypermethylation with most sites reaching
close to 100%methylation (Figure 2B). In the edited clones, both
FXS NPC clones showed clear hypomethylation, with most sites
completely unmethylated (Figure 2B). Quantification of all sites
showed that the average methylation of the FMR1 promoter in
WT and edited WT NPCs was 0.2% and 0.7%, respectively (Fig-
ure 2C). In FXSNPCs, average promoter methylation was as high
as 87.4%; the average promoter methylation of edited FXS
NPCs reached only 0.2% in both clones, similar to the levels
observed in WT NPCs (Figure 2C).
To analyze changes to the chromatin structure of the FMR1
gene, we employed chromatin immunoprecipitation against
histone 3 tail acetylation (H3 Ace) and histone 3 K4 methylation
(H3 K4meth), which indicate a transcriptionally active chromatin
state, and against histone 3 K9 methylation (H3 K9meth), which
indicates a repressed chromatin state and is associated withCell Reports 13, 234–241,FMR1 silencing (Coffee et al., 1999,
2002). Both markers for active chromatin,
H3 Ace and H3 K4meth, were markedly
upregulated following the CGG repeat
editing, and the repressive chromatinmarker H3 K9meth was significantly downregulated (Figure 2D).
In addition, expression levels of APRT, CRYAA, and FMR1
were analyzed in WT and FXS iPSCs using RT-PCR. Expression
analysis verified the correlation between expression and
epigenetic modifications (Figure S2B). These results indicate
that the ablation of the CGG repeats had an epigenetic effect
on the methylation status and chromatin state of the FMR1
promoter.
Restoration of FMRP Levels in Edited FXS Clones
Lastly, we validated the presence of the FMR1 protein (FMRP),
using immunocytochemistry staining in edited iPSC lines as
well as their parental lines. As expected, undifferentiated FXS
iPSCs stained negative for FMRP, in contrast to WT iPSCs,
which stained positive for FMRP (Figure 3A). This result was
further validated by western blotting to ensure a more sensitiveOctober 13, 2015 ª2015 The Authors 237
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Figure 3. Restoration of FMRP in Edited FXS
Cells
(A) Detection of FMRP in WT iPSCs (WT), patients’
iPSCs (FXS), and edited clones (E1 and E3) by
immunochemistry. Undifferentiated cells grown on
feeder-free media were fixed and stained with the
indicated antibodies. DAPI signals (blue) indicate
the total cell presence in the image. Scale bars,
50 mm.
(B) Immunoblot analysis of FMRP in WT, edited WT
(E1), FXS, and edited FXS clones (E1 and E3).
GAPDH was used as a loading control.
(C) The detection of FMRP in NPCs of each cell type
was confirmed by immunoblot analysis. GAPDH
was used as a loading control.
(D) The detection of FMRP in WT, patient (FXS), and
edited iPSC clones (E1 and E2) by immunochem-
istry. Mature neurons differentiated for 60 days from
each line were fixed and stained with the indicated
antibodies. DAPI signals (blue) indicate the total cell
presence in the image. Scale bars, 50 mm.detection of FMRP (Figure 3B). In line with our transcription and
epigenetic results, we found that the levels of FMRP were
restored in the edited FXS iPSC lines E1 and E3. All edited lines
showed similar staining of OCT4 compared with their parental
lines (Figure 3A). Furthermore, other pluripotency markers
showed similar expression levels in both edited lines and their
parental lines, as detected by qPCR analysis (Figure S2C). This
result suggests that the procedure leading to the deletion of
the repeats did not have a negative effect on the undifferentiated
status of the edited clones. Edited ESC lines also were analyzed
and showed staining of FMRP similar to that of their isogenic
parental ESCs (Figure S2D). Next, NPCs derived from FXS
iPSC clones E1 and E3 also were analyzed for the presence of
FMRP by western blotting, in which they showed high levels of
FMRP (Figure 3C).
We further examined whether the presence of FMRP could be
sustained in mature neurons derived from edited FXS iPSC238 Cell Reports 13, 234–241, October 13, 2015 ª2015 The Authorsclones. To address this issue, WT and
FXS iPSCs as well as their isogenic edited
lines were differentiated into mature neu-
rons (Kim et al., 2010, 2012). We then
stained these preparations for FMRP and
microtubule-associated protein 2 (MAP2),
a mature neuron marker. All differentiated
cell lines showed positive staining for
MAP2, indicating successful differentia-
tion into mature neurons (Figure 3D).
Reassuringly, mature neurons differenti-
ated from FXS iPSC clones E1 and E2
stained positive for FMRP, unlike neurons
derived from their parental non-edited
FXS iPSCs (Figure 3D). To investigate
any potential effect of the reactivated
protein, we analyzed gene expression of
edited FXS mature neurons compared
with their isogenic parentally derived
neurons. Our gene expression analysisdemonstrated that, of the few genes that were differentially ex-
pressed between edited and non-edited FXS neurons, there
was enrichment for different glutamate receptor genes. Several
glutamate receptor genes showed more than a 2-fold reduction
in RNA levels after editing (Figure S2E), whereas other key
neuronal genes displayed similar expression levels (Figure S2F).
This result correlates with a previous study that found dysregu-
lation of glutamate receptor activity in FXS neurons (Do¨len et al.,
2007). All together, the results show that genotypic correction
generated by deletion of the abnormal repeats can restore
FMR1 gene expression and the levels of FMRP in FXS iPSCs
and their neural derivatives.
DISCUSSION
Trinucleotide repeat expansions play a role in several neurolog-
ical, neurodegenerative, and neuromuscular disorders such as
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Figure 4. FMR1 Reactivation Model
In FXS iPSCs, FMR1 is silenced because of the presence of the full mutation
of CGG repeats and their methylation, which affects the gene’s promoter.
After removal of the CGG repeats by RGEN, the promoter is released from
its repressive markers and is completely demethylated. Demethylation of
the FMR1 promoter allows the gene to be transcribed and, hence, FMR1 is
reactivated.Huntington’s disease, FXS, spinocerebellar ataxia, andmyotonic
dystrophy (Pearson et al., 2005). In FXS, CGG repeat expansion
in the 50-UTR of the causative gene FMR1 is linked to the devel-
opment of the disease phenotype, although the disease mecha-
nisms are not yet fully understood. During the last several years,
correction of genetic defects using programmed nucleases has
been attempted for several genetic diseases (Yusa et al., 2011;
Sebastiano et al., 2011; Yin et al., 2014; Long et al., 2014;
Maetzel et al., 2014; Li et al., 2015). Among these attempts,
it has been demonstrated that expanded CAG repeats can be
edited in Huntington’s disease patient cells using the traditional
homologous recombination (HR) or Cas9-mediated HRmethods
(An et al., 2012, 2014). However, in our study, we attempted a
deletion-mediated correction of abnormal CGG repeat expan-
sion without the use of a WT allele or the use of an exogenous
donor sequence, but rather through NHEJ induced by the
Cas9 nuclease.
Because individuals with less than 55 CGG trinucleotide
repeats have normal FMR1 expression and because a lower
number of repeats allows for accurate sequencing of repeat
portions and their flanking regions, we first tested our dele-
tion-mediated correction approach in WT iPSCs and WT
ESCs. As a result, CGG repeats, including some of the flankingCregions, were successfully deleted in the WT cells. We then
applied this approach to FXS patients’ iPSCs and ESCs and
succeeded in restoring FMR1 expression. No difference was
observed in the ability of edited cell lines to differentiate into
NPCs and mature neurons when compared to the abilities of
their parental cell lines.
In our sequencing analysis, we frequently observed deletions
in corrected iPSC/ESC lines as well as in RGEN-transfected
HEK293T cells. We speculate that some of these deletions may
have been induced by microhomology-mediated end joining
(MMEJ) that can cause variable-size deletions by base pairing
between two short microhomologous sequences near the DSB
region created by the engineered nucleases (McVey and Lee,
2008; Bae et al., 2014b). Our hypothesis that some deletions
may have been caused by MMEJ is supported by the fact that
numerous GC repeats were found in the upstream and down-
stream regions of CGG repeats, and by the fact thatmicrohomol-
ogous sequences such as GGC and CGG were observed on
both sides of the deletion in the case of 49- and 112-bp deletions
(Figure S1C). Other deletions and insertions in general may have
been induced by NHEJ.
The results of this study showed the reactivation of FMR1 at
the RNA, methylation, chromatin modification, and protein
levels. Taking our current findings together with our previous re-
sults (Urbach et al., 2010; Eiges et al., 2007; Bar-Nur et al.,
2012), we propose a model in which the presence of more
than 200 CGG repeats is necessary, but not sufficient, for the
silencing of FMR1. The presence of the full mutation is recog-
nized during differentiation as a site for DNA methyltransferase
activity, leading to full methylation of the CGG repeats. These
epigenetic changes spread to the upstream and cause both
DNA methylation of the CpG island at the FMR1 promoter and
the closed chromatin conformation in this region. In this work,
we clearly demonstrate that removal of the CGG repeats in un-
differentiated cells can lead to demethylation of the promoter,
open chromatin conformation, and re-expression of the gene,
all of which are sustained through neural rosette formation and
long-term differentiation into mature neurons. These findings
suggest a maintenance mechanism in which the methylation
status of the promoter is constantly regulated according to the
state of the repeats. Thus, when the repeats are removed, the
FMR1 promoter loses its methylation and shows an upregulation
of active chromatin markers, thereby activating the FMR1 gene
(Figures 2D and 4).
The data presented demonstrate the ablation of full-mutation
trinucleotide repeats and the complete reactivation of a gene
using Cas9 nuclease without the use of a donor sequence
for HR. Our Cas9-mediated method to correct trinucleotide
repeats may be applied on patient-specific cells for gene
correction of various short nucleotide repeat expansion-derived
diseases, such as spinocerebellar ataxia and myotonic dystro-
phy. Further work on edited FXS iPSCs should be done to
understand the full impact of the reactivation of FMRP and
may reveal yet unknown functions of this important protein.
This method for gene correction can be applied easily in
many labs and holds a great potential for the study of trinucle-
otide repeat disorders as well as future research for novel
therapies.ell Reports 13, 234–241, October 13, 2015 ª2015 The Authors 239
EXPERIMENTAL PROCEDURES
Cas9-Encoding Plasmid and Transfections
Cas9 and sgRNA expression plasmids were purchased from ToolGen.
Potential off-target sites were computationally searched using Cas-OFFinder
(http://www.rgenome.net/; Bae et al., 2014a). Human iPSCs and ESCs were
pulsed with Cas9 and sgRNA-encoding plasmids as previously described
(Park et al., 2014).
Isolation of Clonal Cells and PCR Analysis
To isolate clonal populations of edited cells, each colony that had been
identified by PCR with a deletion in the CGG repeats was dissociated into
single cells and re-seeded onto a new feeder layer as previously described
(Park et al., 2014).
DNA Methylation Analysis
For DNA methylation analysis, genomic DNA was purified using the Nucleo-
Spin Tissue kit (Macherey-Nagel) according to the manufacturer’s protocol.
Pyrosequencing was performed by EpigenDx according to standard proce-
dures, with a unique set of primers developed by EpigenDx for targeting 22
CpG sites at the FMR1 promoter.
Chromatin Immunoprecipitation
For chromatin immunoprecipitation, FXS and edited FXS iPSCs were har-
vested, fixated, and cross-linked with formaldehyde solution, lysed, and son-
icated. Chromatin was cleared using salmon sperm agarose beads (Millipore)
for 1 hr at 4C. Immunoprecipitation of chromatin was performed overnight
using an anti-acetylated histone H3 antibody (Millipore 06599), an anti-meth-
ylated histone H3 at lysine 4 antibody (Millipore 17614), and an anti-methylated
histone H3 at lysine 9 antibody (Millipore 17648). For more detailed informa-
tion, see the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.08.084.
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